BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38138508)

  • 1. Bench to Bedside Development of [
    Challapalli A; Barwick TD; Dubash SR; Inglese M; Grech-Sollars M; Kozlowski K; Tam H; Patel NH; Winkler M; Flohr P; Saleem A; Bahl A; Falconer A; De Bono JS; Aboagye EO; Mangar S
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteers.
    Challapalli A; Sharma R; Hallett WA; Kozlowski K; Carroll L; Brickute D; Twyman F; Al-Nahhas A; Aboagye EO
    J Nucl Med; 2014 Feb; 55(2):256-63. PubMed ID: 24492392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [
    Dubash S; Inglese M; Mauri F; Kozlowski K; Trivedi P; Arshad M; Challapalli A; Barwick T; Al-Nahhas A; Stanbridge R; Lewanski C; Berry M; Bowen F; Aboagye EO
    Theranostics; 2020; 10(19):8677-8690. PubMed ID: 32754271
    [No Abstract]   [Full Text] [Related]  

  • 4. [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography.
    Leyton J; Smith G; Zhao Y; Perumal M; Nguyen QD; Robins E; Arstad E; Aboagye EO
    Cancer Res; 2009 Oct; 69(19):7721-8. PubMed ID: 19773436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
    DeGrado TR; Baldwin SW; Wang S; Orr MD; Liao RP; Friedman HS; Reiman R; Price DT; Coleman RE
    J Nucl Med; 2001 Dec; 42(12):1805-14. PubMed ID: 11752077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of
    Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
    Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
    How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
    Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics.
    Li Y; Inglese M; Dubash S; Barnes C; Brickute D; Braga MC; Wang N; Beckley A; Heinzmann K; Allott L; Lu H; Chen C; Fu R; Carroll L; Aboagye EO
    Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
    DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
    Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of
    Palard-Novello X; Beuzit L; Gambarota G; Le Jeune F; Garin E; Salaün PY; Devillers A; Querellou S; Bourguet P; Saint-Jalmes H
    Ann Nucl Med; 2019 Jan; 33(1):47-54. PubMed ID: 30219990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE; Kairemo K
    Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.